Home > Publications Database > Inverse association between the anticholinergic burden and hippocampus volume in a population-based cohort across the entire adult age range. > print

001     163452
005     20240321115501.0
024 7 _ |a pmc:PMC9213601
|2 pmc
024 7 _ |a 10.1007/s11357-021-00497-w
|2 doi
024 7 _ |a pmid:34940948
|2 pmid
024 7 _ |a 2509-2715
|2 ISSN
024 7 _ |a 0161-9152
|2 ISSN
024 7 _ |a 1574-4647
|2 ISSN
024 7 _ |a 2331-3765
|2 ISSN
024 7 _ |a 2452-0756
|2 ISSN
024 7 _ |a 2509-2723
|2 ISSN
024 7 _ |a altmetric:119703410
|2 altmetric
024 7 _ |a 2152-4041
|2 ISSN
024 7 _ |a 2331-3773
|2 ISSN
037 _ _ |a DZNE-2022-00212
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 0
|e First author
|u dzne
245 _ _ |a Inverse association between the anticholinergic burden and hippocampus volume in a population-based cohort across the entire adult age range.
260 _ _ |a [Cham]
|c 2022
|b Springer International Publishing
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710944025_2066
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY)
520 _ _ |a Many medications of different indications have a relevant anticholinergic activity. The anticholinergic burden of medication has been shown to have significant effects on the cognition and the risk for cognitive impairment and dementia particularly in older patients. So far, most of the studies used data from geriatric patients and the effect of the anticholinergic burden on brain structures is still unexplored. Our study aimed to analyze possible associations of hippocampus and cholinergic basal forebrain volumes as vulnerable brain structures for the development of dementia and the anticholinergic burden in a population-based cohort of non-demented participants spanning the adult age range from 21 to 80 years. We analyzed associations between medication-related anticholinergic burden and structural MRI volumes from participants (n = 3087, 52.2% female) of the population-based 'Study of Health in Pomerania' (SHIP). Anticholinergic burden was obtained from the current medication plan using the Anticholinergic Burden Scale (ACB). All analyses were adjusted for age, sex, education, and total intracranial volume. We found statistically significant associations between the ACB and the left and right hippocampus volume but not for the basal forebrain cholinergic system. Complementary voxel-based analysis across all participants revealed FWE-corrected (p = < 0.05) clusters in the temporo-parietal regions reaching into frontal areas, showing reduced volumes with higher ACB scores. We identified an association between anticholinergic burden of medication on hippocampal volume suggesting a potential inverse effect of such medication. This association highlights the importance of a careful prescription of medication with anticholinergic activity at any adult age.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Cognitive impairment
|2 Other
650 _ 7 |a Hippocampus
|2 Other
650 _ 7 |a Medication
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Cholinergic Agents: therapeutic use
|2 MeSH
650 _ 2 |a Cholinergic Antagonists: adverse effects
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: chemically induced
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: drug therapy
|2 MeSH
650 _ 2 |a Dementia
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Hippocampus: diagnostic imaging
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
700 1 _ |a Wucherer, Diana
|0 P:(DE-2719)2810631
|b 1
|u dzne
700 1 _ |a Ittermann, Till
|b 2
700 1 _ |a Völzke, Henry
|b 3
700 1 _ |a Bülow, Robin
|b 4
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 5
|u dzne
700 1 _ |a Grabe, Hans Jörgen
|0 P:(DE-2719)2811781
|b 6
|u dzne
700 1 _ |a Wittfeld, Katharina
|0 P:(DE-2719)2810491
|b 7
|u dzne
700 1 _ |a Teipel, Stefan Johannes
|0 P:(DE-2719)2000026
|b 8
|e Last author
|u dzne
773 _ _ |a 10.1007/s11357-021-00497-w
|0 PERI:(DE-600)2886418-9
|n 3
|p 1715-1726
|t GeroScience
|v 44
|y 2022
|x 2509-2723
856 4 _ |u https://pub.dzne.de/record/163452/files/DZNE-2022-00212.pdf
|y OpenAccess
909 C O |o oai:pub.dzne.de:163452
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810631
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811781
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2810491
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GEROSCIENCE : 2021
|d 2022-11-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-05-04
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b GEROSCIENCE : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 1
920 1 _ |0 I:(DE-2719)5000001
|k AG Grabe
|l Biomarkers of Dementia in the General Population
|x 2
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)5000001
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21